Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
Authors:
- Jacopo TroisiJacopo Troisi
- Claudia CinqueCCClaudia Cinque
- Luigi GiuglianoLGLuigi Giugliano
- Steven SymesSSSteven Symes
- Sean RichardsSean Richards
- David AdairDADavid Adair
- Pierpaolo CavalloPierpaolo Cavallo
- Laura SarnoLSLaura Sarno
- Giovanni ScalaGSGiovanni Scala
- Maria CaiazzaMCMaria Caiazza
- Maurizio GuidaMGMaurizio Guida
Open Access
- 23 March 2019
- journal article
- research article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 12 (1) , 1-11
Abstract
Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. ClinicalTial.gov, NCT03608813 . Registered 1st August 2018 - Retrospectively registered, .Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (FARB 2017)
This publication has 72 references indexed in Scilit:
- Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcomeBMC Pregnancy and Childbirth, 2014
- Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysisBMC Medicine, 2012
- Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop GroupFertility and Sterility, 2012
- Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin PolytherapyPLOS ONE, 2011
- Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression dataBioinformatics, 2011
- Recommendations for Planning Pilot Studies in Clinical and Translational ResearchClinical and Translational Science, 2011
- Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysisFertility and Sterility, 2011
- Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopyChemical Society Reviews, 2011
- Relative power and sample size analysis on gene expression profiling dataBMC Genomics, 2009
- Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controlsBiochemical and Biophysical Research Communications, 2002